Biotech Industry · us
Matchpoint raises $150 million; oral T-cell modulator expected to enter clinical development in 2027
The funding will support MPT-062’s progress toward early proof of efficacy in humans and advance additional autoimmune disease candidates. Whether it can precisely modulate dysregulated immune responses remains a question for clinical trials.
With the concept of modulating immune responses taking shape as an oral drug, the next hurdle is determining whether it can work safely in humans. Matchpoint Therapeutics announced on October 7 that it had completed a $150 million Series B financing to advance its lead candidate, MPT-062, toward clinical trials. According to the company’s plans, this oral T-cell modulator is expected to enter clinical development in 2027.
The financing was co-led by Nextech Invest and Norwest. Participating investor T1D Fund also published the same announcement, confirming that it joined Invus, BB Biotech and BOLD Longevity Growth as new investors, with existing shareholders continuing to participate. Kanishka Pothula of Nextech Invest and Brian Matesic of Norwest will join the board, giving the two lead investors a greater role in corporate governance.
The central use of the funding is to advance MPT-062 to clinical proof of concept, using early human studies to assess whether the drug demonstrates its intended therapeutic effects. The announcement describes it as a candidate targeting excessive T-cell activation but does not disclose its specific molecular target, priority disease indications or trial design. It is therefore not yet possible to determine which patient population will be the first to evaluate it.
MPT-062 is built on Matchpoint’s covalent small-molecule development platform. The company combines chemical biology, covalent chemistry, structure-guided drug design and computational methods to identify oral molecules that act on targets previously considered difficult to drug. The clinical value of this strategy still depends on whether candidates can achieve their intended effects while maintaining sufficient selectivity and safety; this announcement provided no related experimental data.
Beyond the lead candidate, the financing will also support other autoimmune and inflammatory disease programs. Matchpoint has another development program funded under an agreement signed with Novartis in July 2025, which will continue to advance. However, this announcement did not disclose that program’s target, progress or any additional collaboration terms, so it cannot be taken as evidence that Novartis has expanded the collaboration.
This financing provides Matchpoint with resources to move into human studies, but clinical validation still stands between securing funding and demonstrating that a drug works. The company and its investors published the same announcement, rather than two independent sets of efficacy evidence. As the planned 2027 development timeline approaches, specific indications, trial arrangements and subsequent safety and efficacy results will bring this oral immune-modulation strategy into clearer focus.